Thymidine Phosphorylase Antibody [P-GF.44C] | 33-768

Thymidine Phosphorylase Antibody [P-GF.44C] | 33-768 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Human recombinant full length protein was used as the immunogen for this Thymidine Phosphorylase antibody.

Research Area: Signal Transduction

Tested Application: IHC-P, IP, WB

Application: IP: 1-2ug/500ug lysate
IHC (FFPE) : 1-2 ug/ml for 30 min at RT
WB: 0.5-1 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Thymidine Phosphorylase antibody to be titered up or down for optimal performance.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: P-GF.44C

Isotype: IgG1

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Thymidine phosphorylase, TP, Gliostatin, Platelet-derived endothelial cell growth factor, PD-ECGF, TdRPase, TYMP, ECGF1

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Recognizes a 485 amino acid protein (55 kDa monomer / 110 kDa homodimer) , identified as platelet-derived endothelial growth factor (PD-ECGF) , also called Thymidine Phosphorylase (TP, Tymp) or Gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic) . Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5 -deoxy-5-fluorouridine to 5-FU) . High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites.